Ganetespib (STA-9090)

Catalog No.S1159

Ganetespib (STA-9090) Chemical Structure

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
In DMSO USD 302 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.

    Cell, 2017, 168(5):856-866. Ganetespib (STA-9090) purchased from Selleck.

    Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

  • Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 NYfKTHdpSXCxcITvd4l{KEG|c3H5 NWG4WW9QOzBxOECvNVUxNzJ3MDDuUS=> M2W5dVI1NzR6L{eyJIg> MoT4bY5lfWOnczDkc5NmKGSncHXu[IFvfCCrbnT1Z5Rqd25ib3[gZZBweHSxc3nz MnfxNlU5QDJ3NUC=
MV411 NGLZeFBCeG:ydH;zbZMhSXO|YYm= MVyzNE85OC9zNUCvNlUxKG6P MVKyOE81QC95MjDo NGnk[GNqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM> NFXseIgzPTh6MkW1NC=>
MGC-803 NF22[Y9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV[wMlEuOTByMDDuUS=> M{PudVczKGh? NYfEXlZrcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MW[yOVU6ODhyNR?=
SGC-7901 MlHFR4VtdCCYaXHibYxqfHliQYPzZZk> M4juflAvOS1zMECwJI5O NWftVHBxPzJiaB?= Mn;NbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NEP6e2kzPTV7MEiwOS=>
MKN-28 NHTUN|BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlfENE4yNTFyMECgcm0> NIHIU4c4OiCq MVTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M1m3cFI2PTlyOEC1
MGC-803 NHzuOm5HfW6ldHnvckBCe3OjeR?= NHu5OmMxNjFvMUCwNEBvVQ>? M36xWlI1KGh? M3XObIlv\HWlZYOgS|IwVSClZXzsMYN6[2ynIHHydoV{fA>? NFPBU2YzPTV7MEiwOS=>
HCT-116 NHfqXmlHfW6ldHnvckBCe3OjeR?= NF7XUlA2OG6P NHPNOW0zPCCq M1u1cGROW09? MXPpcoR2[2WmIFewM2cyKGG{cnXzeC=> MnrsNlUzOTB5OUS=
HT-29 M3m5SGZ2dmO2aX;uJGF{e2G7 MWq1NI5O NH2wWIszPCCq MnL0SG1UVw>? Mn21bY5lfWOnZDDHNE9IOSCjcoLld5Q> NWDMbnZDOjV{MUC3PVQ>
SCC25 MXTDfZRwgGmlaYT5JGF{e2G7 Mn6zNVAwPTBibl2= M3LqcVI1KGh? M170foRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=> NVzLcIxIOjV{MEW0N|A>
FUDA NUnCfpppS3m2b4jpZ4l1gSCDc4PhfS=> M4THdlExNzVyIH7N MUmyOEBp NWLKeWV1\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 NV3oWmM4OjV{MEW0N|A>
Detroit562 MVvDfZRwgGmlaYT5JGF{e2G7 NFm0VosyOC93MDDuUS=> Mni3NlQhcA>? Mn\M[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 NHPESpozPTJyNUSzNC=>
CAL27 Mmq0R5l1d3irY3n0fUBCe3OjeR?= MonrNVAwPTBibl2= M{HIb|I1KGh? NWTIZZZu\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 M3u5PFI2OjB3NEOw
DSH1 NYXIRm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZibl2= NV24cmlqOjR5OES4N|k>
SW-1710 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rpeGlEPTB;NjDuUS=> MnLlNlQ4QDR6M{m=
T24 NHf5bFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTQTWM2OD15IH7N MlzPNlQ4QDR6M{m=
RT112 NGfnW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PUXGlEPTB;OTDuUS=> NVXxbWlnOjR5OES4N|k>
639-V MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13pSWlEPTB;MUCgcm0> M{nLbVI1Pzh2OEO5
SCaBER Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m3RWlEPTB;MUCgcm0> MVWyOFc5PDh|OR?=
BFTC M3TIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF5IH7N M17zXVI1Pzh2OEO5
J82 NEXTXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnOyTWM2OD1zODDuUS=> MnLxNlQ4QDR6M{m=
HT-1376 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX3TWM2OD1{MTDuUS=> NWD6do5MOjR5OES4N|k>
647-V MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHNXHM1UUN3ME2yO{BvVQ>? MnPDNlQ4QDR6M{m=
UM-UC3 NWT1cFBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\WXJFTUUN3ME2zN{BvVQ>? MYGyOFc5PDh|OR?=
LB831-BLC NU\iPGRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTN2IH7N MWSyOFc5PDh|OR?=
KU-19-19 NVXReGk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnviTWM2OD1|NjDuUS=> MoTHNlQ4QDR6M{m=
35612 NInZVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon0TWM2OD1|ODDuUS=> M4P4ZVI1Pzh2OEO5
5637 NHvFdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf3TWM2OD12NDDuUS=> NF\MT48zPDd6NEizPS=>
HT-1197 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLHTWM2OD13MzDuUS=> NYPCcWFVOjR5OES4N|k>
MGH-U3 NYLIOnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTV|IH7N NIjtSYEzPDd6NEizPS=>
TCCSUP NG\HU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjsU2ZKSzVyPUG0NkBvVQ>? NIjDbVEzPDd6NEizPS=>
RT4 NY\TT4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;tO2VKSzVyPUG3N|Mhdk1? MnmzNlQ4QDR6M{m=
SW780 NXjTN|M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3nTHo3UUN3ME2zOFUyKG6P NF\pVZgzPDd6NEizPS=>
RKO MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fQUGlEPTB;NDDuUS=> MXSyOFY5Ojd2Nx?=
LS-411 N NVPJeZdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nJSmlEPTB;NTDuUS=> MkXRNlQ3QDJ5NEe=
SW620 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r2W2lEPTB;ODDuUS=> M2rCbFI1Pjh{N{S3
HCT-15 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G5SGlEPTB;ODDuUS=> MU[yOFY5Ojd2Nx?=
HuTu-80 M1vpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M373WWlEPTB;MUOgcm0> M17qeFI1Pjh{N{S3
HCT 116 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHaTWM2OD1zNDDuUS=> NEThd3QzPDZ6Mke0Oy=>
COLO-205 NEG1NGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S4OmlEPTB;MUSgcm0> MnnHNlQ3QDJ5NEe=
NCI-H747 M4HId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF5IH7N NF[ySI4zPDZ6Mke0Oy=>
COLO-678 M3rZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvpb29zUUN3ME2yNUBvVQ>? NUX1WGlZOjR4OEK3OFc>
LoVo MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO3TWM2OD1{MjDuUS=> NFL6emczPDZ6Mke0Oy=>
LS-1034 NGT0fYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f2cGlEPTB;M{Ggcm0> M3fGU|I1Pjh{N{S3
SNU-C2B M3f6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR3IH7N M3TEWFI1Pjh{N{S3
LS-123 NWTCUXppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H6TmlEPTB;N{Ogcm0> Ml3hNlQ3QDJ5NEe=
SK-CO-1 M4rU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3aTJVKSzVyPUixJI5O MmLINlQ3QDJ5NEe=
HCC2998 NHq5dGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF{ODDuUS=> NYDH[YFMOjR4OEK3OFc>
MDA-MB-231 NH;BdmJHfW6ldHnvckBCe3OjeR?= NXy3UpVXOTByIH7N NYK4WpRMOzBibXnu M4fTXIlvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDITWYuOc7z M172TFI1OjR6Mk[1
MDA-MB-435 MVTGeY5kfGmxbjDBd5NigQ>? MWexNFAhdk1? NV7DVIo{OzBibXnu NXrtc45{cW6qaXLpeJMh[WOldX31cIF1cW:wIH;mJGhKTi1zzsG= MkjQNlQzPDh{NkW=
BT-20  M3zMNWZ2dmO2aX;uJGF{e2G7 M3rLfVExOC9{NUCgcm0> M3nRdlI1KGh? MUfy[ZN2dHSnZDDpckBiKGSxc3Wt[IVx\W6mZX70JIRme3SjYnnsbZpifGmxbjDv[kBGT0[ULDDJS2YuUVJuIF3FWEwh[W6mIFPSRWY> Mk\zNlQyPzN3NEG=
MDA-MB-231 MUDGeY5kfGmxbjDBd5NigQ>? M3HaOVExOCCwTR?= MV[yOEBp MYnpcohq[mm2czD0bIUhdWmpcnH0c5J6KGGwZDDpcpZie2m4ZTDjZZBi[2m2edMg MUiyOFE4OzV2MR?=
H82 NXnqd|JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[2TWM2OD1|MD6yO{BvVQ>? NGnRV2kzPDF4NkWwOS=>
GLC4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJyLkS3JI5O M1rVS|I1OTZ4NUC1
H69 NEfJSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjVSWF2UUN3ME24N{4{PiCwTR?= MVeyOFE3PjVyNR?=
H128 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTZ7LkW1JI5O NYm5[3B5OjRzNk[1NFU>
H146 NEfnXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLjTWM2OD1{OD61NUBvVQ>? NGHKWY8zPDF4NkWwOS=>
H187 NHvnelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvMR|RtUUN3ME2yOE46QSCwTR?= NVLnN45UOjRzNk[1NFU>
H526 NFvW[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJzLk[0JI5O M37mS|I1OTZ4NUC1
N592 M4\mcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF2LkGyJI5O MY[yOFE3PjVyNR?=
H620 NUnpNndOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvkUoJKSzVyPUOyMlY4KG6P NY\YS297OjRzNk[1NFU>
H792 M3\CT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR3LkC3JI5O MYGyOFE3PjVyNR?=
H1173 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi2NpRKSzVyPUGyMlYzKG6P NGT0S4IzPDF4NkWwOS=>
AC3 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7PRoxJUUN3ME2yOU46KG6P NELDWXMzPDF4NkWwOS=>
H82 NVLndWNtTnWwY4Tpc44hSXO|YYm= NX[3XG5bOzBibl2= M{PhT|czKGh? M13hcIlv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> M4n4S|I1OTZ4NUC1
GLC4 NYLiN5pyTnWwY4Tpc44hSXO|YYm= M3\EW|MxKG6P MnvaO|IhcA>? MWTpcoR2[2W|IIDldpNqe3SnboSgS|IwVSCyaHHz[UBienKnc4S= MX[yOFE3PjVyNR?=
H146  NFviNoJHfW6ldHnvckBCe3OjeR?= NVrGTpVvOzBibl2= NWfS[HN4PzJiaB?= NVrTOGh{cW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1 MUeyOFE3PjVyNR?=
OVCAR-5 NHi0SItE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3vIfVAuOTByMDDuUS=> MXy3NkBp MXXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MUmyN|kxODF|Nh?=
OVCAR-8 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXiwMVExODBibl2= M3vzOlczKGh? M{TVPYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M13UN|I{QTByMUO2
A1847 NXPNc4s4S2WubDDWbYFjcWyrdImgRZN{[Xl? NHmwOogxNTFyMECgcm0> NILReGo4OiCq MV7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NGr1[nMzOzlyMEGzOi=>
SKOV-3 NELDUJlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2jod|AuOTByMDDuUS=> NIC5[XA4OiCq NEW5VoJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MmLENlM6ODBzM{[=
OVCAR-5 NXzhTXAzSXCxcITvd4l{KEG|c3H5 MmPSNVAuOTByIH7N NHzNU2wzPC92OD:3NkBp M4PSTIlv\HWlZYOgZZBweHSxc3nzJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62bIm= NGrxblkzOzlyMEGzOi=>
OVCAR-8 NV;CZ4RISXCxcITvd4l{KEG|c3H5 MkS4NVAuOTByIH7N MWCyOE81QC95MjDo MknxbY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= MXeyN|kxODF|Nh?=
A1847 NHqxdWlCeG:ydH;zbZMhSXO|YYm= NFrUfVAyOC1zMECgcm0> MkP0NlQwPDhxN{KgbC=> M2jse4lv\HWlZYOgZZBweHSxc3nzJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62bIm= MYOyN|kxODF|Nh?=
H2228 MnfhR4VtdCCYaXHibYxqfHliQYPzZZk> MoHHNE0yODByIH7N NF[wUZU4OiCq MWDJR|UxRTF|IH7N MkezNlM2OzN{NkW=
H3122 MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlzvNE0yODByIH7N MlO5O|IhcA>? MoHFTWM2OD1zMDDuUS=> NVnhVJNVOjN3M{OyOlU>
K008 MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkmzTWM2OD14MDDuUS=> M{Sy[FI{PDF6NUKz
K028 NHLWcYtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MW\JR|UxRTh2IH7N MYiyN|QyQDV{Mx?=
K029 NVrrNWJUS2WubDDWbYFjcWyrdImgRZN{[Xl? M3SzOWlEPTB;NE[gcm0> M1fL[VI{PDF6NUKz
M23 MofNR4VtdCCYaXHibYxqfHliQYPzZZk> Mln6TWM2OD1|Nz61JI5O MWqyN|QyQDV{Mx?=
K033 Mlq5R4VtdCCYaXHibYxqfHliQYPzZZk> M131PGlEPTB;N{WuOUBvVQ>? M1vQbFI{PDF6NUKz
K008 MWDGeY5kfGmxbjDBd5NigQ>? MlvDNlUxKG6P NVXBU3BJOjRiaB?= MUTpcoR2[2W|IFeyJIFzemW|dB?= NYjC[|JUOjN2MUi1NlM>
K028 NXfuR5QzTnWwY4Tpc44hSXO|YYm= MnnqNlUxKG6P NWrETXdvOjRiaB?= NXnn[np5cW6mdXPld{BIOiCjcoLld5Q> NVzCd3JpOjN2MUi1NlM>
K029 NXzhdVA4TnWwY4Tpc44hSXO|YYm= NXLCNVNrOjVyIH7N Ml3NNlQhcA>? MYXpcoR2[2W|IFexJIFzemW|dB?= NEfzeIgzOzRzOEWyNy=>
M23 Mnr6SpVv[3Srb36gRZN{[Xl? MlmyNlUxKG6P MlHiNlQhcA>? NGrlRnZqdmS3Y3XzJGcyKGGwZDDHNk9OKGG{cnXzeC=> Ml7NNlM1OTh3MkO=
K033 NWDNbW1UTnWwY4Tpc44hSXO|YYm= NFjZSWQzPTBibl2= MlTPNlQhcA>? NU[z[443cW6mdXPld{BiKG2xZHXzeEBqdmO{ZXHz[UBqdiCJMTDwc5B2dGG2aX;u M3HkUFI{PDF6NUKz
K008 NGjYZnBCeG:ydH;zbZMhSXO|YYm= Mmn6NVAxKG6P M1v4dFczKGh? M3zwNJNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? NXLjfVZrOjN2MUi1NlM>
K028 NVjLbHlESXCxcITvd4l{KEG|c3H5 M4LOeVExOCCwTR?= NVnEfJJNPzJiaB?= Mnzvd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? MX:yN|QyQDV{Mx?=
K029 M2jzemFxd3C2b4Ppd{BCe3OjeR?= MXWxNFAhdk1? M3W5e|czKGh? MUDzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ M3;M[lI{PDF6NUKz
M23 MVLBdI9xfG:|aYOgRZN{[Xl? NUPGVG1YOTByIH7N NHLV[3U4OiCq M3u5fpNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? M12xV|I{PDF6NUKz
K033 NXTvcFY1SXCxcITvd4l{KEG|c3H5 Ml;2NVAxKG6P Mle2O|IhcA>? NWPOZW8{e2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= NF3xNGgzOzRzOEWyNy=>
RD NV;nN|RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPpOW1KSzVyPUigcm0> MV6yN|MxOzd2MR?=
Rh41 NIfmW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonMTWM2OD1zMD60JI5O M3PTN|I{OzB|N{Sx
Rh18 NWXNdlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X3[2lEPTB;Nj6yJI5O M1\5VFI{OzB|N{Sx
Rh30 Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfCTWM2OD13Lk[gcm0> MlTBNlM{ODN5NEG=
BT-12 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rkUGlEPTB;MUSuN{BvVQ>? NEW2cYwzOzNyM{e0NS=>
CHLA-266 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ5LkGgcm0> NH3iS2MzOzNyM{e0NS=>
TC-71 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRwNTDuUS=> NV\2eoxJOjN|MEO3OFE>
CHLA-9 NF3RU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTRwNjDuUS=> NG\XVFgzOzNyM{e0NS=>
CHLA-10 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;IRmlEPTB;NT63JI5O MXGyN|MxOzd2MR?=
CHLA-258 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvQTWM2OD14LkSgcm0> NYLiWG45OjN|MEO3OFE>
SJ-GBM2 NIHvNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LLXGlEPTB;MUKuPUBvVQ>? NGDI[3QzOzNyM{e0NS=>
NB-1643 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jNUWlEPTB;Nz60JI5O M17LbVI{OzB|N{Sx
NB-EBc1 NFq2eXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW4TWM2OD1zNj64JI5O M{W1OVI{OzB|N{Sx
CHLA-90 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT3SFNKSzVyPUKyMlMhdk1? NFLjVnIzOzNyM{e0NS=>
CHLA-136 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ|LkKgcm0> MYqyN|MxOzd2MR?=
NALM-6 M2nUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFzLkegcm0> MWeyN|MxOzd2MR?=
COG-LL-317 NV\QPZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTRwNDDuUS=> NUm3PHp1OjN|MEO3OFE>
RS4;11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF|LkWgcm0> NFj3NWIzOzNyM{e0NS=>
MOLT-4 NFXUbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTZeppKSzVyPUGwMlYhdk1? MUiyN|MxOzd2MR?=
CCRF-CEM (1) NYe2cWR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF{LkWgcm0> MX6yN|MxOzd2MR?=
CCRF-CEM (2) M3jyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTdwMjDuUS=> Ml;tNlM{ODN5NEG=
Kasumi-1 NICyc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHrTWM2OD13Lkigcm0> MmDINlM{ODN5NEG=
Karpas-299 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTlwNjDuUS=> NXX6OYpjOjN|MEO3OFE>
Ramos-RA1 M4TuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWra[oc{UUN3ME23MlQhdk1? NVLNTHpwOjN|MEO3OFE>
LNCaP Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRThibl2= MYOyN|E2OjByNB?=
VCaP M4TFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjaTWM2OD15IH7N MWWyN|E2OjByNB?=
H1355 NFrVeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrQbIhKSzVyPUWgcm0> MY[yN|AyOjJ2OB?=
H157 NF\EUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTdibl2= MYqyN|AyOjJ2OB?=
H460 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{WwWWlEPTB;ODDuUS=> MlHTNlMxOTJ{NEi=
IA-LM MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFyIH7N NILuWHIzOzBzMkK0PC=>
HOP-62 NGjKNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv0dm5qUUN3ME2xNUBvVQ>? M{fpW|I{ODF{MkS4
H23 NG\EdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vZPWlEPTB;MUGgcm0> MnXxNlMxOTJ{NEi=
H2030 M3XlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF{IH7N NEKydmszOzBzMkK0PC=>
H441 M4rSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjDZndKSzVyPUG0JI5O NV7RSpBKOjNyMUKyOFg>
H2212 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF5IH7N MVSyN|AyOjJ2OB?=
SK-LU-1 M3;GXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF6IH7N NH3CU4gzOzBzMkK0PC=>
H2009 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF7IH7N M{Hrd|I{ODF{MkS4
H1792 M{jBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK1Rm9KSzVyPUKwJI5O M1nXfVI{ODF{MkS4
COR-L23 M4TnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO5emNWUUN3ME2yNkBvVQ>? MVuyN|AyOjJ2OB?=
H727 M{PL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnQeHJ6UUN3ME2yPEBvVQ>? M3u3eFI{ODF{MkS4
H1734 NHjxUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm1dWhSUUN3ME2yPEBvVQ>? NFu1XW4zOzBzMkK0PC=>
H358 NGLxe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDiTZk3UUN3ME2yPUBvVQ>? MVGyN|AyOjJ2OB?=
A549 NWqzSZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR|IH7N MlflNlMxOTJ{NEi=
H2122 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr5PGI6UUN3ME21N{BvVQ>? NWm5SlZ[OjNyMUKyOFg>
Calu-1 M2S0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTV6IH7N M4rX[lI{ODF{MkS4
Calu-6 M4Tsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnNTWM2OD14NDDuUS=> NE\aXGUzOzBzMkK0PC=>
NCI-H1975 NU\NOI1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S1[|Q5KGh? NITmT2hKSzVyPUG2JI5O NYXOOWZPOjJzNES2OlU>
NCI-H1975 M3TCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TacVczKGh? MnznTWM2OD16IH7N M13KWVIzOTR2Nk[1

... Click to View More Cell Line Experimental Data

In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+45% PEG 300+ddH2O 11mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 9, 2014 Phase 1
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 --
NCT02389751 Active, not recruiting Esophageal Cancer M.D. Anderson Cancer Center|Synta Pharmaceuticals Corp. April 2015 Phase 1
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02261805 Terminated Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2
NCT02272478 Recruiting Acute Myeloid Leukaemia|Myelodysplastic Syndrome Cardiff University|Cancer Research UK October 2014 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID